Alkermes Plc. (ALKS)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

88 SIDNEY ST CAMBRIDGE, MA 02139-4136

Alkermes Plc. develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. Headquartered in Cambridge, MA, this pharmaceutical company also operates research and manufacturing facilities in Massachusetts and Ohio.

Data based on most recent fiscal year report
Market Cap2.917 Billion Shares Outstanding157.52 Million Avg Volume1.668 Million
1-Yr BETA vs S&P TR1.592 Current Ratio2.89 Quick Ratio2.63
View SEC Filings from ALKS instead.

View recent insider trading info

Funds Holding ALKS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALKS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HENWOOD GERALDINE PRESIDENT AND CEO

  • Officer
  • Director
291,194 2020-01-18 0

GAYNOR RICHARD PRESIDENT OF R&D

  • Officer
221,500 2020-01-12 3

ROBINSON JAMES A. JR.

  • Director
12,480 2020-01-10 2

WILSON FRANK ANDERS

  • Director
5,834 2020-01-09 2

DIXON WENDY L

  • Director
12,536 2019-12-31 1

POPS RICHARD F DIRECTOR AND CEO, ALKERMES PLC

  • Officer
  • Director
716,433 2019-11-14 12

LANDINE MICHAEL J SVP, CORP DEV., ALKERMES, INC.

  • Officer
185,122 2019-11-13 9

WYSENSKI NANCY

  • Director
0 2019-11-12 2

FRATES JAMES M SVP, ALKS INC; CFO ALKS

  • Officer
213,925 2019-09-13 5

SNYDERMAN NANCY LYNN MD

9,083 2019-08-22 1

MITCHELL PAUL J

  • Director
15,000 2019-07-01 5

STEJBACH MARK

  • Director
0 2019-06-19 0

COOKE SHANE

  • Director
82,074 2019-06-12 1

HOPKINSON CRAIG C. SVP, MED DEV/MED AFFAIRS, CMO

  • Officer
6,877 2019-06-07 3

BLOOM FLOYD E

  • Director
0 2019-05-22 1

BREYER ROBERT A

  • Director
0 2019-05-22 1

ANSTICE DAVID W

  • Director
0 2019-05-22 1

GAFFIN DAVID JOSEPH SVP, CLO, ALKERMES, INC.

  • Officer
48,550 2019-05-09 5

BROWN IAIN MICHAEL SVP FINANCE & CAO, ALKS INC.

  • Officer
30,402 2019-03-01 4

BIBERSTEIN KATHRYN L EVP/CAO/CCO/CRO ALKS INC;

  • Officer
182,073 2018-03-01 0

EHRICH ELLIOT EVP, R&D & CMO, ALKERMES, INC.

  • Officer
57,056 2017-05-28 0

PUGH GORDON G SVP, COO & CRO, ALKERMES, INC.

  • Officer
No longer subject to file 2016-12-31 0

PETERSON REBECCA SVP, CORPORATE COMMUNICATIONS

  • Officer
2,644 2015-10-05 0

BOTKIN JAMES L SVP, ALKERMES GAINESVILLE LLC

  • Officer
No longer subject to file 2013-12-31 0

SKALETSKY MARK B

  • Director
No longer subject to file 2013-11-13 0

ELAN CORP PLC

ELAN SCIENCE THREE LTD

  • 10% Owner
No longer subject to file 2012-03-13 0

RICH ALEXANDER

  • Director
0 2011-12-15 0

WALL MICHAEL A

  • Director
No longer subject to file 2011-09-16 0

BROECKER DAVID A PRESIDENT & CEO

  • Officer
106,616 2009-06-16 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

WILSON FRANK ANDERS - Director

2019-12-04 A 11,200 a 11,200 0.00 direct

GAYNOR RICHARD - Director

2019-12-04 A 11,200 a 11,200 0.00 direct

WILSON FRANK ANDERS - Director

2019-12-04 A 61,800 a 61,800 0.00 direct

GAYNOR RICHARD - Director

2019-12-04 A 61,800 a 61,800 0.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments